Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma-Reference-Cited by-同舟云学术

Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma

Published:2012-05-22 Issue:11 Volume:120 Page:935-940
ISSN:0903-4641
Container-title:APMIS
language:en
Short-container-title:APMIS

Author:

Hinge Maja¹,Ingels Helene A.S.²,Slotved Hans-Christian²,Mølle Ingolf¹

Affiliation:

1. Department of Hematology; Aarhus University Hospital; Aarhus C

2. Department of Microbiological Surveillance and Research; Statens Serum Institut; Copenhagen; Denmark

Publisher

Wiley

Subject

Microbiology (medical),General Medicine,Immunology and Allergy,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0463.2012.02922.x/fullpdf

Reference26 articles.

1. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group;Lenhoff;Blood,2000

2. Multiple myeloma: review of 869 cases;Kyle;Mayo Clin Proc,1975

3. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Council Adult Leukaemia Working Party;Augustson;J Clin Oncol,2005

4. Influence of treatment and response status on infection risk in multiple myeloma;Perri;Am J Med,1981

5. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules;Cesana;Haematologica,2003

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma and infections in the era of novel treatment modalities;Leukemia Research;2024-08

2. Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma;Frontiers in Oncology;2023-04-21

3. COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review;Therapeutic Advances in Vaccines and Immunotherapy;2023-01

4. Prevention of infections including vaccination strategies in multiple myeloma;American Journal of Hematology;2022-11-24

5. Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response;British Journal of Haematology;2022-02-17